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IMMEDIATEHYPOTENSIVE EFFECTS OF AN ORAL DOSE
The hypotensive response to 1-hydrazinophthalazine administered parenterally has been discussed in a previous communications To determine the immediate effects of oral administration the drug was given to hospitalized patients after allowing sufficient time for stabilization of blood pressure. The initial dose was 50 mg., but if this amount failed to produce a significant hypotensive response or side-effects, the dosage was increased after 24 hours or longer by 50 mg. increments until a definite response was obtained.
Sixteen hypertensive patients were studied (table 1). Following ingestion of 1-hydrazinophthalazine the reduction of systolic blood pressure in the entire group averaged 10 per cent (range 0 to 32 per cent) in the supine position and 21 per cent (range 4 to 42 per cent) in the erect position. The depression of diastolic blood pressure averaged 16 per cent (range 4 to 42 per cent) in the supine position and 24 per cent (range 4 to 50 per cent) in the erect position for the entire group. Thus, the percentile reduction was greater in diastolic pressure than in systolic.
Six of these patients were given only 50 mg. of 1-hydrazinophthalazine because of minor side effects, and it is probable that further reCirculation, Volume V, June 1952 duction of blood pressure could have been obtained with larger dosages. Conversely two of the five patients given 150 mg. of the drug exhibited reductions of less than 15 per cent in both the erect and supine positions.
The onset of action usually appeared within 20 to 30 minutes, reached a maximum between 30 and 120 minutes and usually disappeared after two to four hours. However, when dosages approached toxic levels, marked reductions of blood pressure occurred and evidence of drug activity persisted for as long as eight or even 12 hours. significant reduction of blood pressure. In these patients dosages had been increased from 50 mg. two to four times daily to 124 or 150 mg. two to four times daily.
Six patients exhibited a significant hypotensive effect in the early period of treatment which, however, became less and less marked despite elevation of dosage. The following case illustrates this apparent development of tolerance.
J. J., a Negro man, age 52, with hypertension known for one year, entered the hospital because of congestive heart failure. The nonprotein nitrogen Two of the six patients who had exhibited hypotensive responses only during the early period of treatment with 1-hydrazinophthalazine also had severe renal disease with chronic uremia. In neither of these was there evidence of improvement in renal function as judged by the degree of nitrogen retention, albuminuria and the urinary sediment. Three patients with only mild renal involvement, one of which showed a sustained hypotensive response to 1-hydrazinophthalazine and two a hypotensive response only during the early phase of treatment, reported a decrease in nocturia after two to four weeks of treatment. patients. The headache usually centered in the occipital area and was described as being grinding and pounding in character. It usually lasted four to six hours and did not respond to aspirin or caffeine. It always was accompanied by a definite hypotensive effect and occurred after doses varying from 50 to 150 mg.
During regular administration, when dosages were elevated rapidly and at short intervals of four to six hours, headache appeared frequently after three or four doses had been administered. However, when dosage was begun at levels of 50 mg. and increases were made gradually or when the doses were widely separated, for example, by a 12-hour interval, headache occurred less frequently. In the 17 
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cases treated in this way headache occurred in four and in only two was it severe. In two the headache was mild and disappeared in one case without change in dosage, and in the other with slight reduction of dosage.
Moderate tachycardia with heart rates of 90 to 100 beats per minute was present in all patients in whom hypotension had been induced by 1-hydrazinophthalazine. Palpitation was complained of in five patients given this drug continuously and in two given single doses. Transient dyspnea accompanied by slow deep respirations was associated with marked reductions of blood pressure in two patients during the early phase of continuous therapy. In order to combat these fluctuations of arterial pressure, other agents which could be administered orally were given midway between the doses of hexamethonium. Examples of such agents have been veratrum viride, 1-hydrazinophthalazine, the dihydrogenated alkaloids of ergot, N-benzyl-N-phenoxyisopropyl-beta-chloroethylamine (SKF 688-A), and the imidazoline compounds Regitine (C-7337) and Priscoline. The most effective of these when alternated with hexamethonium has been 1-hydrazinophthalazine.
Nine hospitalized patients who manifested a fluctuating type of blood pressure while receiving injections of hexamethonium at 12-hour intervals were given 1-hydrazinophthalazine orally midway between the doses of hexamethonium (table 2) . Usually the patients were given hexamethonium at 9:00 a.m. and 9:00 p.m. and 1-hydrazinophthalazine at 3:00 a.m. and 3:00 p.m. The blood pressure was recorded in the supine position immediately before and one hour after each medication as well as at other times of day. During the control period prior to any medication (which lasted five days or longer), the average blood pressure for the entire group of patients was 210/140 and the range 160/115 to 250/165. (fig. 2) . During 14 weeks of hospitalization, while under intensive treatment with many hypotensive agents, there had been no sustained reduction of blood pressure. Following hexamethonium, Anatensol or Veriloid there was a temporary reduction of arterial pressure, but none of the drugs produced sustained responses due apparently to the gradual development of tolerance.
All medication was then discontinued for the next 15 days during which period the average blood pressure was 240/155 (range 230/150 to 260/170). Frequent and severe headaches soon returned. However, since the patient did not respond or quickly developed tolerance to all medications he was discharged on no specific therapy.
Two weeks later the patient was readmitted acutely and severely ill. During the short time that he had been home all symptoms had become rapidly and progressively worse. The blood pressure was 230/170. The fundi now exhibited papilledema of three diopters. There was mental confusion, severe headache, vomiting and pulmonary congestion with dyspnea and orthopnea and the nonprotein nitrogen was 50 mg. per 100 cc.
Because of the previous experience demonstrating an apparent development of resistance to all hypotensive agents when used continuously it was decided to use various drugs in rotation, so that no single agent was used twice in succession, in an attempt to forestall the development of tolerance. The doses of the drugs used were 25 to 50 mg. of hexamethonium ion intramuscularly, 25 to 150 mg. of 1-hydrazinophthalazine (C-5968) orally, 0.3 nmg.
of mixed dihydrogenated alkaloids of ergot (CCK-179)* intramuscularly, 0.25 to 0.50 mg. of Anatensol intramuscularly and 50 mg. of Priscoline crally. These were given at six-hour intervals in various rotations so that no single agent was administered more frequently than once every 24 hours. Sodium restriction to 200 mg. daily was continued.
Initially dosages of these substances (C6, C-5968, Anatensol and CCK-179) were administered in that order at six-hour intervals. There was a pronounced fall of arterial pressure from the admission level of 230/170 to an average level of 175/120, accompanied by marked clinical improvement. After several days it was noted that the greatest reduction of arterial pressure occurred after injection of hexamethonium, whereas the poorest responses were observed to follow the ergot preparation and Anatensol. Hence, the latter agent was replaced by a second injection of hexamethonium. Over the five-week period that This resistance to the hypotensive effect of the drug was not lasting, however, and sensitivity to the initial small doses of 1-hydrazinophthalazine could be restored by omitting the medication for one week. In addition it was apparent that the greater the interval between doses the less marked was the degree and the more delayed the development of such resistance.
Over long periods in the treatment of hypertension, tolerance in varying degree has developed following almost all hypotensive agents, including sodium nitrite,14 veratrum viride,"5 the dihydrogenated alkaloids of ergot,1 Priscoline and Regitine,'7 SKF-688A, and hexamethonium.10 Because of this phenomenon we have leaned increasingly toward the concept that effective long-term chemotherapy of essential hypertension using presently available agents must utilize these drugs alternately. This rotation might prevent or at least allay the development of a significant degree of tolerance. The most effective of these combinations in our experience has been 1-hydrazinophthalazine alternated with hexamethonium. In many of the cases receiving hexamethonium alone twice per day (in the morning and at bedtime) the greatest elevation of blood pressure occurred in the evening whereas the effect of the dose taken at bedtime frequently carried over until next morning. In these cases 1-hydrazinophthalazine was given only once per day, in the midafternoon, and thus the necessity for awakening to take the drug at 3:00 a.m. was obviated.
In many instances tolerance to hexamethonium can be overcome by progressive elevation of dosage. Hence, it is possible in some cases to maintain a sustained hypotensive effect by using large oral doses of hexamethonium frequently administered. But such complete and lasting autonomic blockade also induces in varying degree gastrointestinal atony, paralysis of visual accommodation, disabling postural hypotension, lethargy and impaired cerebration, impotence in the male, shivering in a cool environment due to failure of cutaneous vasoconstriction, loss of bladder tone and cessation of salivary secretion. Although some of these effects can be partially controlled with the use of parasympathomimetic agents such as Urecholine,9 many of these patients are unable to carry on a normal existence. Thus, although a sustained hypotension is attainable in some instances by oral administration of large doses of hexamethonium, such intensive treatment may on occasion produce fatalities'9 and frequently induces disabling side effects. Therefore, in long-term therapy it has seemed more desirable and considerably safer to produce intermittent rather than continuous ganglionic blockade supplementing and prolonging the hypotensive effect with 1-hydrazinophthalazine.
In addition to its synergistic effect when used with hexamethonium, 1-hydrazinophthalazine also appeared to have an additive effect when given with veratrum viride. Three patients in whom the control of blood pressure was unsatisfactory using veriloid alone obtained an improved hypotensive response when 1-hydrazinophthalazine was added once or twice daily.'8
The side effects produced by 1-hydrazinophthalazine appeared to be related to the dosage level and also to the frequency of administration. Doses of this drug (C-5968) which produced a profound hypotension also were most likely to be associated with side effects, particularly headache and palpitation. If treatment was initiated using doses of 25 to 50 mg. and increased over a period of a week to the most effective range these undesirable reactions were minimized. They also were seen much less frequently when the dosage interval was no less than 12 hours and especially when treatment was alternated with hexamethonium.
In addition to increasing renal blood flow, 1-hydrazinophthalazine appears to have other desirable attributes, including effectiveness by the oral route of administration, absence of serious toxicity and ability to lower diastolic as well as systolic blood pressure. As to the ultimate place of 1-hydrazinophthalazine in the therapy of essential hypertension, it is suggested by these studies that the drug probably is of greatest value when used in conjunction with other agents, particularly when alternated with hexamethonium. 2. Attempts to maintain a significant reduction of arterial pressure by frequent administration of the drug usually led to the rapid development of tolerance. The latter could be partially overcome by (a) increase in dosage, (b) prolonging the interval between doses, and (c) omitting the medication entirely for a period of one week. Persistent reductions of arterial pressure over prolonged periods were rarely attained with 1-hydrazinophthalazine alone.
3. Side effects, observed inconstantly, included severe headache, tachycardia with palpitation, flushing of the skin, dizziness and weakness, and rarely, dyspnea and nausea and vomiting. Such reactions could be minimized by gradual increases in and wide spacing between dosages of 1-hydrazinophthalazine.
4. 1-Hydrazinophthalazine (C-5968) was most effective when used alternately with other hypotensive agents, particularly with hexamethonium (C6). Such intermittency of dosage appeared to minimize the development both of side effects and of tolerance and resulted in a greater and more sustained reduction of blood pressure than when either agent was used alone.
